Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Torsemide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 10/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | BRS3 | P32247 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Torsemide SCHEMBL29395363 | 1.00 | TBXA2R (1.00) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL4015063 | 1.00 | TBXA2R (1.00) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL29369134 | 1.00 | TBXA2R (1.00) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL28460508 | 0.99 | TBXA2R (0.98) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL4838293 | 0.99 | TBXA2R (0.98) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL4827506 | 0.99 | TBXA2R (0.98) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL6315139 | 0.99 | TBXA2R (0.98) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL6307778 | 0.99 | TBXA2R (0.98) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL22687888 | 0.98 | TBXA2R (0.96) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A | |
| Torsemide SCHEMBL7256454 | 0.98 | TBXA2R (0.96) | TBXA2RKDM4ECYP3A4CYP2C9HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 17008 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747611-A1 | OPTICAL ELECTRODE ANALYTE DETECTION SYSTEM AND METHODS OF USE | Vital Biosciences Inc. (CA) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| EP-3934654-B1 | ISTAROXIME OR ITS METABOLITE PST-3093 FOR USE AS INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | WINDTREE THERAPEUTICS INC (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108532-A1 | COMPOSITION FOR PREVENTING HEART DISEASES CAUSED BY PULMONARY HYPERTENSION AND TREATING HEART, AND FUNCTIONAL FORMULATION COMPRISING SAME | CARESIDE CO., LTD. (KR) | 2026-04-23 | — | — | US | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| EP-4710928-A2 | METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| US-12521402-B2 | Biomarker and drug combinations for heart failure prediction | Endothelium Scanning Nanotechnology Limited (AU) | 2026-01-13 | — | — | US | claimed |
| EP-4673221-A1 | POTENT TRANSTHYRETIN (TTR) STABILIZATION IN TTR AMYLOIDOSIS PATIENTS RECEIVING ACORAMIDIS | Eidos Therapeutics, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| US-20260000679-A9 | BIOMARKER AND DRUG COMBINATIONS FOR HEART FAILURE PREDICTION | ENDOTHELIUM SCANNING NANOTECHNOLOGY LTD (AU) | 2026-01-01 | — | — | US | claimed |
| EP-0550689-A4 | — | — | 1994-02-16 | — | — | EP | claimed |
| EP-0550689-A1 | IBUPROFEN-DIURETIC COMBINATIONS | MERCK & CO. INC. (US) | 1993-07-14 | — | — | EP | claimed |
| WO-1992005786-A1 | IBUPROFEN-DIURETIC COMBINATIONS | MERCK & CO., INC. (US) | 1992-04-16 | — | — | WO | claimed |
| WO-1991001491-A1 | OPTICAL AND PYROLYZATE ANALYZER APPARATUS AND METHOD | UNION OIL COMPANY OF CALIFORNIA (US) | 1991-02-07 | — | — | WO | claimed |
| EP-0253226-B1 | AQUEOUS ALCALINE INJECTABLE SOLUTION OF TORASEMID READY FOR USE AND PROCESS FOR PREPARATION THEREOF | Roche Diagnostics GmbH (DE) | 1990-06-06 | — | — | EP | claimed |
| EP-0355554-A1 | Medical sponge and method of making same | SEALED AIR CORPORATION (US) | 1990-02-28 | — | — | EP | claimed |
| EP-0212537-B1 | PROCESS FOR THE PREPARATION OF A STABLE MODIFICATION OF TORASEMIDE, AND MEDICAMENTS CONTAINING TORASEMIDE | Roche Diagnostics GmbH (DE) | 1990-01-03 | — | — | EP | claimed |
| US-4861786-A | Composition for a stable vein compatible injectable solution of torasemide process for the preparation and method of use | BOEHRINGER MANNHEIM GMBH (DE) | 1989-08-29 | — | — | US | claimed |
| US-4822807-A | FAST-DISSOLVING | BOEHRINGER MANNHEIM GMBH (DE) | 1989-04-18 | — | — | US | claimed |
| US-4743693-A | REARRANGEMENT OF CRYSTAL STRUCTURE | BOEHRINGER MANNHEIM GMBH (DE) | 1988-05-10 | — | — | US | claimed |